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Abstract
Manufacture of red blood cells (RBCs) from progenitors has been proposed as a method to reduce reliance on donors. Such a
process would need to be extremely efficient for economic viability given a relatively low value product and high (2 × 1012) cell
dose. Therefore, the aim of these studies was to define the productivity of an industry standard stirred-tank bioreactor and
determine engineering limitations of commercial red blood cells production. Cord blood derived CD34+ cells were cultured
under erythroid differentiation conditions in a stirred micro-bioreactor (Ambr™). Enucleated cells of 80% purity could be
created under optimal physical conditions: pH 7.5, 50% oxygen, without gas-sparging (which damaged cells) and with mechan-
ical agitation (which directly increased enucleation). O2 consumption was low (~5 × 10
–8 μg/cell.h) theoretically enabling
erythroblast densities in excess of 5 × 108/ml in commercial bioreactors and sub-10 l/unit production volumes. The bioreactor
process achieved a 24% and 42% reduction in media volume and culture time, respectively, relative to unoptimized flask
processing. However, media exchange limited productivity to 1 unit of erythroblasts per 500 l of media. Systematic replacement
of media constituents, as well as screening for inhibitory levels of ammonia, lactate and key cytokines did not identify a reason
for this limitation. We conclude that the properties of erythroblasts are such that the conventional constraints on cell
manufacturing efficiency, such as mass transfer and metabolic demand, should not prevent high intensity production; further-
more, this could be achieved in industry standard equipment. However, identification and removal of an inhibitory mediator
is required to enable these economies to be realized. Copyright © 2016 The Authors Journal of Tissue Engineering and Regen-
erative Medicine Published by John Wiley & Sons Ltd.
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1. Introduction
Blood transfusions are one of the most common clinical
interventions worldwide with ~21 million donated blood
components transfused each year in the USA alone. In-
creasing demand due to aging populations, challenges of
adventitious agent screening, or requirement for specific
immuno-phenotypes, has created a growing search for al-
ternative sources to public donation. New uses for red
blood cells (RBCs) such as targeted drug delivery may in-
crease this demand further (Bourgeaux et al., 2016).
There is evidence that transfusion of homogenously young
RBCs may have clinical benefit by decreasing the transfu-
sion frequency of chronically transfused patients (Bosman,
2013; Luten et al., 2008). One proposed solution to these
issues is the manufacture of RBC from stem or progenitor
cells potentially providing an unlimited supply of cells in
an optimal age distribution (Zeuner et al., 2012).
Anucleate RBCs have successfully been produced
in vitro from a variety of cell sources including
haematopoietic stem cells such as cord blood CD34+ cells,
adult mobilised peripheral blood, and bonemarrowCD34+
cells (Neildez-Nguyen et al., 2002; Giarratana et al., 2005;
Miharada et al., 2006; Fujimi et al., 2008; Giarratana
et al., 2011). Recently, approaches using human pluripotent
cells, both induced and embryonic, have also been re-
ported, although challenges with control of appropriate
lineage and development of adult phenotype remain
(Qiu et al., 2008; Lu et al., 2008; Lapillonne et al., 2010;
Dias et al., 2011; Chang et al., 2011; Kobari et al., 2012).
Due to the exceptionally high numbers of erythroblast stage
cells required to be maintained in viable culture in any can-
didate production process, common late stage manufactur-
ing challenges exist irrespective of initial cell source.
Challenges associated with the scale-up of any cell cul-
ture bioprocess include maintaining consistency, quality
and quantity of the cell product whilst minimizing cost
of production (Rousseau et al., 2014; Timmins and
Nielsen, 2009). This is particularly fraught with RBC
production due to the requirement for relatively extreme
process intensification whilst avoiding detrimental effects
on cells, and where there is little understanding of the
sensitivities of each stage of the progressively maturing
erythroid phenotype to common bioprocess operations.
In particular, robust erythroblast enucleation to produce
reticulocytes and then fully mature RBCs has been
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problematic in vitro and the mechanisms still remain to be
fully elucidated (Kingsley et al., 2004; Lee et al., 2004).
With respect to cost of production, RBC is an example of
a high dose product where cost of goods reduction is a pri-
ority for commercial viability. It has been estimated that
one unit of cultured RBCs would cost $8000–15,000 to
produce using current processes, compared to $200–230
for one unit of donated blood (Zeuner et al., 2012). The
primary reason for this high cost is expensive media com-
ponents required for in vitro differentiation and matura-
tion multiplied by large culture volumes. This has led to
calls for research to identify and address the fundamental
barriers to efficient production of erythroid cells
(Rousseau et al., 2014).
Cost effective production of RBCs will require high
density cell culture. Conventional culture densities are
considered high at 1 × 107 cells/ml, yet this would still
require a 200-l final volume to produce a single unit or
2 × 1012 cells. To achieve a final harvest of 2 × 1012
cells in a 5-l volume will require a density of 4 × 108
cells/ml. Neither of these volumes accounts for the pro-
duction chain to reach the final cell number, or produc-
tion overage required for cell impurity or cell losses in
downstream processing. Clearly there is a need to under-
stand the productivity of RBC manufacture at scale, and
the nature of the limitations, to enable the
manufactured blood field to move forward. In order to
address this, we have used a model system of differenti-
ation of CB CD34+ cells to RBCs in a ml-scale stirred
tank bioreactor system.
It has previously been shown that CB CD34+ cells can
proliferate and differentiate to erythroid cells in a scaled
down version of industry standard production equipment,
the stirred microbioreactor system, Ambr™ (Glen et al.,
2013; Hsu et al., 2012; Ratcliffe et al., 2012). In the pres-
ent study, the intensification limits (bioreactor operation,
gas transfer, media usage) of cells in such standard equip-
ment were explored to determine current productivity
and limiting mechanisms with respect to key criteria: cost
of goods (system volume, media volume per cell and pro-
cess time per cell) and quality (enucleated cells). This is
important to allow the field to take an informed approach
to address the engineering and scientific challenges that
need to be overcome to generate an economically viable
product.
2. Materials and methods
Unless otherwise stated, reagents were purchased from
Sigma–Aldrich (Dorset, UK).
2.1. CD34+ cell culture
Fresh umbilical cord-derived mononuclear cells were sup-
plied by the Anthony Nolan Cell Therapy Centre (http://
www.anthonynolan.org/clinicians-and-researchers/cord-
blood-services) with informed consent and NREC ethical
approval. CD34+ cells were isolated via positive selection
using CD34 antibody-labelled microbeads as per the man-
ufacturer’s instructions (Miltenyi Biotec, Germany).
Mixed donor CD34+ cells (>70% purity) were cryopre-
served prior to cell culture. On thaw, CD34+ cells were
cultured in accordance with a three-stage protocol as
described previously (Griffiths et al., 2012). Briefly, cells
were cultured in Iscove’s Modified Dulbecco’s Medium
(IMDM) (Source BioScience) containing 3% (v/v) AB Se-
rum (Sigma), 2 mg/ml human serum albumin (Irvine Sci-
entific, USA), 10 μg/ml Insulin (Sigma), 3 U/ml heparin
(Sigma), 500 μg/ml iron saturated Transferrin (R&D Sys-
tems). In the first stage (days 0–8) this was supplemented
with 10 ng/ml SCF, 1 ng/ml interleukin (IL)-3 and 3 U/ml
erythropoietin (EPO); in the second stage (days 8–11) with
10 ng/ml stem cell factor (SCF), 3 U/ml EPO and in the
final stage (days 11–20) with 3 U/ml EPO. Cells were
cultured in tissue culture flasks at 37°C, 5% CO2 for 3 days,
after which cells were either maintained in control
static culture or transferred to the Ambr bioreactor system
(TAP Biosystems, Royston, UK). Bioreactors were
preconditioned as described previously (Glen et al., 2013)
and vessels were gassed either using a sparge tube or via
the vessel headspace if nonsparged. 0.1% Pluronic F-68
(Gibco, Paisley, UK), impeller speed, pH, and O2 (percent-
age of atmospheric), were varied as specified in results.
2.2. Culture analysis
2.2.1. Cell count and viability
Online cell counting and viability was measured using a
Vi-Cell XR (Beckman Coulter, USA). Population doublings
(PD) were calculated as follows:
PDs ¼ LOG10 CN=CNið Þ½ 3:33f g
CNi ¼ start cell number; and CN ¼ end cell number:
2.2.2. Flow cytometry of erythroid lineage markers
Cells were sampled to FACS tubes (1 × 105/tube) and in-
cubated with preconjugated antibodies CD34-FITC (BD
Biosciences, San Jose, CA, USA), CD235a-PE (BD Biosci-
ences) and DRAQ5 (nuclear stain; BioStatus, Loughbor-
ough, UK) for 20 min at room temperature (RT).
CD235a+/DRAQ5- cells were classified as enucleated.
Samples were analysed using a BD FACSCanto™ II flow
cytometer (BD Biosciences) and gated against specific
isotype controls to determine percentage positive cells.
2.2.3. Assessment of cell morphology
Cells (1–4 × 105) were centrifuged at 300 × gav for 6 min
at RT, supernatant removed, resuspended in 200 μl of me-
dium and centrifuged onto poly-lysine coated microscope
slides (Sigma 3-16 PK centrifuge with a cytology rotor) at
60 × gav for 4 min at RT. Slides were left to air dry over-
night, stained using Leishman’s stain (VWR International,
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Radnor, PA, USA) and mounted with mounting medium
and a glass coverslip. Slides were examined by bright field
microscopy using an Eclipse Ti (Nikon, Tokyo, Japan) at
40× magnification.
2.2.4. High-performance liquid chromatography for
haemoglobin expression
High-performance liquid chromatography (HPLC) globin
chain separation was performed using a protocol modified
from Lapillonne et al. (2010). Cells (106) were centrifuged
at 300 × gav for 6 min at RT, lysed in 50 μl water, and
stored at –80°C. On thaw, samples were centrifuged at
13,000 × gav at 4°C for 10 min and the lysates collected.
Supernatant (10 μl) was injected onto a 1.0 × 250 mm
C4 column (Phenomenex, Macclesfield, UK) with a 42%
to 56% linear gradient between mixtures of
0.1% trifluoracetic acid in water (Buffer A) and 0.1%
trifluoracetic acid in acetonitrile (Buffer B) at flow rate
of 0.05 mL/min for 50 min (Dionex HPLC Ultimate 3000
system; Thermo Fisher Scientific, Camberley, UK). The
column temperature was 50°C and the UV detector set
at 220 nm.
2.2.5. Cytokine analysis
Ten analytes [IL-1β, IL-2, IL-4, IL-6, IL-10, interferon-γ,
tumour necrosis factor-α, transforming growth factor
(TGF)-β1, TGF-β2, and TGF-β3] were quantified from
cell culture supernatant with the Bio-Plex Pro™ Human
Cytokine Group I, 7-plex assay kit and the Bio-Plex Pro
TGF-β, 3-plex assay kit (Bio-Rad Laboratories, Hercules,
CA, USA) according to the manufacturer’s instructions.
Data were acquired using a Bio-Plex-200 suspension
array system and concentrations calculated with Bio-Plex
Manager software 6.1 on a Bio-Plex® MAGPIX™
instrument using a standard curve derived from a
recombinant cytokine standard (supplied by the
manufacturer).
2.2.6. O2 consumption rate
Erythroblasts were taken at a series of time-points and O2
consumption assessed using an O2 sensitive phosphores-
cent probe mixed with cells at 1 × 107/ml in a 96-well
plate format as per manufacturer’s instructions (Cayman
Chemical, Ann Arbor, MI, USA). A FLUOstar Omega plate
reader (BMG Labtech, Orternberg, Germany) recorded
ratiometric time-resolved fluorescence (Excitation
=380 ± 20 nm / Emission =650 ± 50 nm) and O2 con-
sumption (mg/cell.h) was calculated based on a 0.9%
solubility of O2 in saline solution at 37°C under 1
atmospheric pressure (6.7 mg O2/l). Maximum support-
able cell density in commercial scalable systems was
calculated using the formula:
Cell density ¼ Kla C  Cð Þ=R
Where Kla = reported mass transfer coefficient of sys-
tem (/h), C* = saturation O2 concentration (6.7 mg/l),
C = maintenance O2 concentration (3.35 mg/l), and
R = O2 consumption (mg/cell.h).
2.2.7. System medium per cell volumetric productivity
analysis
Erythroblasts were taken at day 7 of culture and volumet-
ric productivity calculated for cultures seeded in fresh me-
dia at 3 × 106/ml, 5 × 106/ml and 5 × 106/ml with 30%
of medium replaced after 5 h:
Volumetricmediumproductivity (volume/cell)=Media
volume used/( I.ert – I).
I (initial cell number), r (growth rate constant, h–1), (t)
time when growth rate becomes inhibited.
Uninhibited growth rate (r) was estimated from an
exponential fit to the first 12 points of each high resolu-
tion (0.75-h counts) growth curve; time of growth inhi-
bition (t) was determined as the point at which cell
numbers deviated from extrapolation of this uninhibited
model.
2.2.8. Media exhaustion studies
Erythroblasts were taken at day 7 of culture, centrifuged
at 300 × gav for 6 min at RT, and resuspended in fresh cul-
ture medium at 3 × 106/ml. Medium and cells were sam-
pled hourly. Controls were cultured without intervention;
experimental supplemented concentrations at 10 h were
2250 mg/l glucose, 292 mg/l glutamine, 1.5% AB serum,
5 ng/ml stem cell factor, 0.5 ng/ml interleukin-3 and
1.5 U/ml erythropoietin alone or in combination as speci-
fied in results. Amino acids (MEM Amino acids 50× solu-
tion, M5550), vitamins (BME Vitamins 100× solution,
B6891) and phosphate (sodium phosphate monobasic,
S5011) were supplemented at initial concentrations.
Ammonium hydroxide and lactic acid were added to
erythroblast cultures at 3 × 105/ml to assess the effect
on cell growth (1.3 mM, 8 mM ammonia; 5 mM, 28 mM
lactate). Metabolite and nutrients were measured (or ver-
ified) using a Cedex Bio HT – Bioprocess Analyser (Roche,
Switzerland).
2.3. Statistics and calculations
Statistical comparisons and design of experiment statisti-
cal design were conducted using Minitab™ software.
ANOVA was used to establish P-values and Tukey’s test
where pairwise comparisons are stated. A minimum of
n = 3, was used to power statistical comparisons. Growth
rate in the presence of inhibitors was calculated from an
exponential fit to a six-point data series over 18 h. Growth
response to supplements was calculated by the rate of
deviation from extrapolated uninhibited exponential
growth. Where percent enucleation is reported, it is
reported to coincide with the peak system proliferation,
avoiding misleadingly high percentage enucleation
figures that occur as cell numbers decline.
The productivity limit of manufactured blood cell therapy
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3. Results
3.1. Erythroblast bioreactor compatibility and cell density
intensification limitations
Three cell-type specific attributes, in combination with the
mass transfer characteristics of a bioreactor, determine
the cell density that can be supported in a culture system:
tolerance to bioreactor operation (and therefore achiev-
able mass transfer), required dissolved O2 level, and O2
uptake rate (OUR). Given the importance of culture inten-
sification to RBC manufacture, each of these was deter-
mined for erythroblast culture.
3.1.1. Tolerance of erythroblast culture to bioreactor agita-
tion and gassing
Mechanical agitation and gas sparging of a cell culture
improves mass transfer and therefore O2 availability to
cells. However, consequent mechanical stress can
reduce cell viability or alter phenotype; in the case of
erythroid lineage cells impeller tip speeds of
>210 mm/s have been reported to be damaging (Chisti,
2001), and gassing can damage cells during bubble
rupture. Further, gas damage can be exacerbated by
mechanical agitation due to bubble break up and
increased bubble to cell surface interface (Chisti,
2000). To test these operational factors, stir speeds of
300 revolutions/min (RPM; 157 mm/s) and 450 RPM
(236 mm/s) in combination with O2 delivery via sparg-
ing through the medium or the reactor headspace were
investigated for effects on cell proliferation and erythro-
blast maturation.
Sparged and stirred bioreactors substantially reduced
erythroblast proliferation relative to static culture. This ef-
fect was increased at higher tip speed with static culture
total PDs (TPD) of 15.3, decreasing to 9.9 and 6.0 at
300 and 450 RPM respectively (p ≤ 0.05). In the absence
of sparging, cell proliferation in the bioreactor was im-
proved, but still reduced relative to static culture
(p ≤ 0.05). However, there was no significant difference
between the different tip-speeds (300 RPM, TPD = 12.0,
450 RPM (TPD = 11.9), or any measured reduction in vi-
ability, indicating that mechanical damage was unlikely to
be the reason for this remaining proliferative deficit in
nonsparged bioreactors (Figure 1A). Addition of the non-
ionic surfactant Pluronic-F68 (PF-68) was investigated to
mitigate sparging induced damage; PF-68 restored
sparged bioreactor cell growth to the level of nonsparged
controls, increasing tolerable O2 input rate, and therefore
increasing potential cell density (Chisti, 2000;
Tharmalingam et al., 2008) (Figure 1A). Enucleated
Figure 1. Erythroid cell proliferation and differentiation is affected by bioreactor operational factors that determine systemmass transfer. Mechanical agitation, gas sparging and
cell protective PF68 were tested for effect on growth and maturation. (A) Growth curves show gas sparging (S) with stirring (300 or 450RPM) greatly reduced cell proliferation;
stirring exacerbated the negative effect of sparging but was not detrimental alone (NS). PF68 supplementation to sparged bioreactors (S, P) protected proliferation from
mechanical damage and was equivalent to nonsparged bioreactors (NS). (B) Example flow cytometry plot of CD235a vs. the nuclear stain DRAQ5 shows clear identification of
the enucleated population (box). (C) In a nonsparged system, higher mechanical agitation supported a higher enucleation rate after 18 days. (D) Mechanical agitation was shown
to have a direct effect on enucleation by transfer of cells from static to bioreactor culture after 19 days; the parallel curves indicate this accelerated enucleation is not associated
with increased enucleated cell fragility [Colour figure can be viewed at wileyonlinelibrary.com]
R. Bayley et al
Copyright © 2016 The Authors Journal of Tissue Engineering and Regenerative Medicine Published by John Wiley & Sons Ltd. J Tissue Eng Regen Med 2017.
DOI: 10.1002/term
RBC production under each condition was evaluated by a
flow cytometry assay of CD235a+/DRAQ5– cells
(Figure 1B). Although protective of growth, PF-68 had a
negative impact on the percentage of enucleated cells at
the end of the process. This negative effect persisted when
PF-68 was removed from the cultures at Day 7
(nonsparged control enucleation =68%, sparged + PF-
68 = 43%, sparged + PF-68 until Day 7 = 44%;
p ≤ 0.05). In the absence of sparging, a higher tip-speed
generated substantially more enucleated product
(Figure 1C). Transfer of cells from static culture to stirred
culture after 19 days resulted in a rapid increase in enu-
cleated cells demonstrating this was a direct effect of stir-
ring on enucleation (Figure 1D).
3.1.2. Effect of dissolved O2 and pH level on erythroblast
culture
The second erythroblast attribute necessary to deter-
mine maximum potential cell density is the dissolved
O2 concentration. Both O2 and pH are reported to effect
erythroid differentiation (Endo et al., 1994; McAdams
et al., 1998; Sarakul et al., 2013); a matrix of pH and
O2 conditions were investigated in the bioreactor sys-
tem to determine relative magnitude of effect and
independence.
Lower dissolved O2 greatly increased the percentage of
enucleated cells (Figure 2A–C). At 25% O2 there were
78% enucleated cells, which was significantly higher than
the 37% enucleated cells observed at 100% O2 (p ≤ 0.01).
pH did not appear to be a significant factor affecting
enucleation; however, pairwise comparison showed the
difference between pH 7.3 and 7.5 to be close to signifi-
cance (p = 0.14); this is in agreement with the advantage
to elevated pH reported previously and our observation of
the persistence of non-CD235a expressing cells at pH 7.3
(data not shown). A rise in the percentage of enucleated
cells occurred with increased pH at intermediate level
O2, indicating sensitivity to pH effect may be greater if dis-
solved O2 is not optimized (Figure 2D). pH and O2 had no
significant effect on total cell proliferation or time to max-
imum product yield, with the TPD ranging from 12.0 to
12.6 in all cultures and the maximum product yield
achieved between 17 and 20 days.
3.1.3. Comparison of the bioreactor produced cells to a
static culture system
The established bioreactor process (pH 7.5/50% O2/450
RPM/nonsparged) was compared to the control static cul-
ture system. After 21 days in culture, a large number of
mature enucleated cells were observed in both systems
Figure 2. Lower dissolved O2 increases the percentage of enucleated cells. (A) Lower dissolved O2 increases the percent of the cell population enucleated (p = 0.004). 25% and
50% O2 form a statistically distinct group from higher O2 levels (p ≥ 0.05). pH is not a statistically significant factor (pairwise comparison indicates the difference between pH 7.3
and 7.5 close to significance, p = 0.14). (B) Cell morphology clearly shows higher enucleation levels at lower O2 (Day 19 cells cytocentrifuged, stained with Leishmans dye, ob-
served with a Nikon Eclipse Ti microscope with a 40× objective. (C) The level of enucleation is higher throughout the culture process at low O2, not just at final harvest. (D)
An interaction chart for pH and O2 suggests a rise in percent enucleation with increased pH may be more significant when O2 is at an intermediate level [Colour figure can be
viewed at wileyonlinelibrary.com]
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with a similar appearance to the adult donor RBC control
(Figure 3A). The mature RBCs cultured in vitro were also
similar in size to adult RBC (static =8.8 μm, bioreactor
=8.3 μm, adult donor control RBC = 8.5 μm;
Figure 3B). The percentage of enucleated cells was
higher in bioreactor cultures (78 ± 4%) compared to
static (54 ± 4%; p ≤ 0.05; Figure 3C), illustrating that
increased homogeneity of enucleated cell product is
achieved in the bioreactor system. Analysis of
haemoglobin expression showed broad equivalence be-
tween static and bioreactor systems, and comparability
to other reports from cord cells (Jin et al., 2014), includ-
ing significant expression of β-globins (Figure 3D). The
approximately 3 TPD deficit in proliferation in bioreac-
tor culture relative to static culture was confirmed as
previously observed (Figure 3E).
3.1.4. Determining specific O2 uptake rate of erythroblasts
The maximum cell density supportable is determined by
the rate of O2 transfer into the medium in the
established bioreactor process relative to the cells OUR
(Xing et al., 2009). Cell OUR was monitored throughout
the CD34+ to RBC differentiation process. Maximal
OUR occurred at Day 6 in both static and bioreactor cul-
ture (static =5.10 × 10–8 μg O2/cell.h and bioreactor
=6.34 × 10–8 μg O2/cell.h; Figure 4). After this point
the OUR of cells in the bioreactor declined and reached
1.69 × 10–8 μg O2/cell.h by Day 19. Cells in static cul-
ture had a more variable OUR following Day 6, but this
still decreased to 9.11 × 10–9 μg O2/cell.h by Day 19.
The known mass transfer characteristics of commercial
scale culture systems (Junker, 2004; Klockner et al.,
2013; Mikola et al., 2007; Nienow et al., 2013) allows
calculation of the density of erythroblasts supportable
in the absence of other culture limitations, and the com-
patibility of those systems with constraints on bioreactor
operation to increase mass transfer (identified above;
Table 1). Calculations are based on consumption rates
of 2.3 × 10–7 μg O2/cell.h to allow a significant (4-fold)
safety margin and indicate that cell densities in excess
of 5 × 108/ml (target density to allow a sub-10 l system
volume/unit of 2 × 1012 cells) should be supportable in
various commercially available bioreactors.
Figure 3. Erythroid cells cultured in the established bioreactor system had reproducibly improved homogeneity but lower total proliferation relative to cells generated in the
control static culture system. (A) Photographs of cells from static, bioreactor and a primary control show mature enucleated cells in both systems (cytocentrifuged onto glass
slides, stained with Leishmans dye, visualised using a Nikon Eclipse Ti microscope equipped with a 40× objective). (B) The diameter of cells in static and bioreactor cultures show
a reduction with time to the size of the primary control red blood cells. This was slightly accelerated in the bioreactor. (C) The percentage of enucleated erythroid cells (CD235a
+/DRAQ5–) in bioreactor cultures at the point of peak proliferation was greater than in the control static culture. (D) Haemoglobin status of cells obtained from static and bio-
reactor cultures after 21 days was similar (HPLC). The percentage indicates the proportion of β haemoglobin chain expression. (E) Cumulative population doublings of cells in
static and bioreactor cultures and associated table shows reduced total proliferation in the stirred bioreactor (n = 5 independent bioreactor runs from separate primary cell iso-
lations, data is mean ± standard error of the mean) [Colour figure can be viewed at wileyonlinelibrary.com]
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3.2. Erythroblast medium volumetric productivity limit
Given that O2 availability was not the primary bioreac-
tor limitation at current culture densities the culture
medium utilisation of the system was assessed. Erythro-
blasts from Day 6 were placed into fresh medium in bio-
reactors at different densities (3 × 106/ml, 5 × 106/ml)
and with an alternate media exchange strategy
(5 × 106/ml with 30% exchange after 5 h) to construct
high resolution growth curves. Exponential growth
models of the first 9 h (12 data points) were all equiv-
alent for growth rate (0.05 1/h) and an excellent fit
(R2 > 96% in all cases) indicating no significant impact
of initial cell density or partial media exchange on
growth rate (Figure 5A). Deviation of the data from
the extrapolated model identified when growth
inhibition occurred; 15.2 h (3 × 106/ml), 12.4 h
(5 × 106/ml), 16.1 h (5 × 106/ml with 30% media change
after 5 h; Figure 5B). The medium replacement rate per
cell produced required to keep erythroblasts in uninhib-
ited growth was strategy dependent suggesting increased
productivity from higher density culture (Table 2); this
bioreactor protocol would require a lower media
volume/unit produced (495 l/unit) compared to the orig-
inal static laboratory protocol (662 l/unit; Table 2). Fur-
ther, the bioreactor protocols maintenance of a ~ 13.9 h
cell doubling time will only require 58% of the
manufacturing facility time relative to the control static
process (~24 h doubling) for any given output, with sub-
stantial cost implications.
3.3. Screening of factors limiting medium volumetric
productivity
Five hundred litres of media per unit of RBCs is still at
least an order of magnitude below economic levels of
intensification. Inhibition of cell growth by depletion of
nutrients was tested by supplementation strategies of key
media component groups including glucose, glutamine,
serum, cytokines (EPO, SCF and IL-3), amino acids, vita-
mins, and phosphate. However, this had no effect on the
point at which growth inhibition occurred (Figure 6A, B).
Further, only a low proportion of available glucose was de-
pleted over the uninhibited growth period (Figure 6D);
other key nutrients including iron, glutamine, and
glutamate also showed negligible consumption rates over
the period prior to growth inhibition (data not shown).
The alternative to medium depletion is production of an
inhibitory factor such as lactate or ammonia (Hassell et al.,
1991); addition of exogenous supplements of either signif-
icantly inhibited growth rate in a linear fashion (p ≤ 0.05;
Figure 6C). The effect of each factor was dependent on the
level of the other with high lactate levels reducing the
inhibitory effect of ammonia. However, to cause the
observed inhibition of growth ammonia/lactate combina-
tions in excess of 4 mM/15 mM respectively would be
necessary; accumulated concentrations of endogenously
produced ammonia (ND i.e. <0.3 mM) and lactate
(~6 mM) at the point of growth inhibition were much
lower (Figure 6D). Additionally, after a brief initial higher
period, the molar ratio of lactate produced to glucose used
Figure 4. O2 is not a factor limiting cell expansion in the Ambr bioreactor system. The specific OUR of erythroblasts at serial time points was monitored via an O2 sensitive fluo-
rescent probe. OUR is low relative to conventional cell lines and declines as cells mature
Table 1. Calculation of the density of erythroblasts achievable in commercial scaled systems based on mass transfer properties in the absence of other culture limitations
(calculated based on 2.3 × 10
–7
μg O2/cell.h to allow a 4-fold safety margin from observed peak OUR); compatibility with erythroblast culture is noted based on the sparging
and mechanical sensitivities presented in Figure 1
System Representative Kla (/h) Theoretical density supported (cells/ml) System compatible with erythroblasts
Pilot scale to large production sparged
stirred tank (1–20 kl)
60–380 1.6 × 10
9
–9.8 × 10
9
No
10–50 l nonsparged stirred vessels 10–100 (depending on agitation and
fill volume)
2.6 × 10
8
–2.6 × 10
9
Yes
200 l nonsparged (i.e. Cultibag Orb) 10–20 2.6 × 10
8
–5.2 × 10
8
Potentially
5–10 l wave bag 2–60 (dependent on rocking rate and head
space gas exchange)
5.2 × 10
7
–1.6 × 10
9
Potentially
Ambr bioreactor system 3–5 8.0 × 10
7
–1.3 × 10
8
Yes
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remained constant at 0.75 with no particular deviation as-
sociated with growth inhibition (Figure 6D). Finally, cul-
tures were screened for the production of potentially
inhibitory cytokines; TGF-β, interferon-γ and tumour ne-
crosis factor-α are prime candidates reported to inhibit ery-
throid growth; IL-1-β, IL-2, IL-4, IL-6 and IL-10 were also
measured as potential feedback influences. TGF-β1 was
the only factor secreted at a relatively high (ng/ml) level
(Figure 6E). Dosing of exogenous TGF-β1 did decrease
specific cell proliferative rate but only by 9% at 10 ng/ml,
a higher dose level and lower inhibition than that observed
in culture (Figure 6F). Although a substantive effect on
proliferative rate was not observed, TGF-β1 did accelerate
erythroblast maturation: 1 ng/ml resulted in a faster in-
crease in CD235a expression, earlier enucleation, and
~30% reduced total proliferative capacity of cells suggest-
ing the cytokine may be responsible for the lower
proliferation/higher enucleation in the bioreactor. How-
ever, the cell specific production rate of TGF-β1 was equiv-
alent in the static and the bioreactor system, showing a
rapid decline in both systems over the first 5 h, after which
it remained relatively stable (Figure 6G). Of further note,
the TGF-β1 was in inactive form (bound to latency associ-
ated peptide) in either static or bioreactor culture system
(≤ limit of detection 1 pg/ml i.e. ≤0.1% of total).
4. Discussion
RBCs as a manufactured product will not become eco-
nomically viable unless fundamental barriers to cell
culture efficiency are identified and addressed. The
work here has shown that the barriers conventionally
associated with high intensity cell production are not
the primary limitations for the field; on the contrary,
erythroblast metabolic characteristics indicate that gas
mass transfer requirements, nutrient use and metabolite
resistance will allow high intensity production in cur-
rent industry standard bioreactor systems. Further, cer-
tain system attributes, such as mechanical stress, can
be advantageously controlled to increase product pu-
rity. This understanding is necessary to inform future
research that will progress the manufactured RBC field.
Any adoption of nonindustry standard bioreactors, or
new bioreactor design, should be based upon specific
requirements of the intensified process. Defining
production limits in current commercial bioreactor
systems is a key starting point; such systems lower
the risks and barrier to entry for product developers
due to regulatory and industrial experience.
Most cell cultures are limited in absolute density by
O2 transfer into the system, and this will determine
the minimum volumetric footprint for the manufactur-
ing bioreactor. The low specific OUR of the erythro-
blasts is at least an order of magnitude beneath those
reported for common cell lines (Ruffieux et al., 1998;
Goudar et al., 2011). Even given the operational con-
straints on actively gassing and agitating the culture
media this enables potentially very high intensity pro-
duction. The frequency with which media needs to be
exchanged to maintain uninhibited exponential growth
is therefore the primary economic constraint. This does
not necessarily force a large volume for the
manufacturing bioreactor, but determines the total vol-
ume of medium used in a given production run.
Allowing cells to drop significantly beneath uninhibited
exponential growth is grossly time, and consequently
cost, inefficient due to the compounding nature of cell
doubling. The observed uninhibited growth rate poten-
tial is encouraging; a 13-h erythroblast doubling time
enables a 4-order of magnitude increase in cell number
in a week. However, the calculated rate of media ex-
change required to achieve this, with many minimally
Figure 5. Volumetric productivity of the system is dependent on media exchange strategy (A) Cells were cultured starting at 3 × 10
6
/ml, 5 × 10
6
/ml, and 5 × 10
6
/ml including a
30% volume exchange after 5 h. Cells initially proliferated at a constant and equivalent rate under all conditions after which growth became inhibited. (B) The initial deviation of
the cell numbers from the extrapolated exponential growth is approximately linear (R
2
> 95%), and can be used to approximate the time point at which growth became inhibited
[Colour figure can be viewed at wileyonlinelibrary.com]
Table 2. The number of cells produced up until the time at which growth becomes
inhibited can be used to calculate the volumetric productivity of each strategy if un-
inhibited growth were maintained. *Significantly (p ≤ 0.05) different from 3 × 10
6
/
ml bioreactor
Condition Start cell density Growth
rate (h)
Doubling
time (h)
Vol (l)/unit
Static Protocol 1.00 × 10
6
0.029 24.25 662
Bioreactor 3.00 × 10
6
0.051 13.93 573
Bioreactor 5.00 × 10
6
0.051 13.93 *495
Bioreactor (30% 5 h
media exchange)
5.00 × 10
6
0.051 13.93 *501
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depleted factors wasted and common metabolites
beneath toxic levels, is economically prohibitive.
A depleted medium factor or a secreted inhibitor
could exhibit the same growth limiting behaviour
observed. However, we have stronger evidence for the
latter given the range of supplementary strategies that
do not promote further cell growth. Further, the main-
tenance of a constant ratio of glucose consumption to
Figure 6. Depletion of medium factors or production of common metabolites and cytokines are not responsible for volumetric productivity limits. (A) As previously, the
deviation of cell growth from the initial exponential rate can be plotted as exponential model residuals vs. time. Supplementation after 10 h with amino acids, vitamins,
or amino acids, vitamins and phosphate do not change the point at which growth becomes inhibited. (B) A wider range of supplementation strategies were tested
including combinations of cytokines, serum, glucose and glutamine. The percent reduction in cells at 24 h compared to that predicted by the exponential model for each
strategy is shown indicating no support of additional cell growth relative to control for any supplementation strategy. (C) Ammonia and lactate both inhibit cell
growth (p ≤ 0.05). An increase in lactate concentration reduces the inhibitory effect of ammonia at high levels of the latter. (D) Lactate accumulates linearly with
increased cell.time. However, at the point of growth inhibition (red dashed line) the level is not inhibitory with reference to (C). Further, glucose and lactate specific
rates do not show any notable change as growth becomes inhibited. (E) A screen of cytokines present in media after cell growth inhibition indicated TGF-β1 as a
primary candidate for feedback growth inhibition. (F) TGF-β1 is shown to be slightly inhibitory to erythroblast cell growth with a maximum of 9% reduction in specific
growth rate over 40 h of culture and 10 ng/ml TGF-β1. (G) TGF-β1 is produced at the same specific rate in static and bioreactor cultures [Colour figure can be viewed at
wileyonlinelibrary.com]
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lactate production suggests this is not a metabolic limi-
tation; such limits would be likely to disrupt the ratio
(Zagari et al., 2013). TGF-β1 was present at high levels,
and (as previously reported (Buscemi et al., 2011)), ac-
celerated erythroblast maturation in a manner similar
to that observed in the bioreactor when exogenously
dosed in to static culture. The equivalent concentration
and inactivity of the endogenous cytokine in both
culture systems initially suggested it was an unlikely
candidate for either growth rate inhibition or total
reduced proliferation in the bioreactor. However,
mechanical forces as low as 40 pN can transiently
activate TGF-β1 from its latent form; it is therefore
reasonably probable that there is a bioreactor specific
effect whilst stirring is applied causing accelerated
maturation (Buscemi et al., 2011). Alternatively, or
additionally, mechanical forces have been reported to
have direct integrin mediated signalling effects that
can influence cell maturation or inhibitory factor
potency (Schwart, 2010). Although this could not
explain the inhibition of proliferative rate (given the
lack of substantive effect of TGF-β1 dosing into the
bioreactor on proliferation rate), other unidentified
inhibitory mediators are likely to be secreted.
Mechanical agitation has been reported to increase
cytokine release and signalling in a number of other
cell types so there is evidence that such factors could
be present at higher levels, or more potent, in a stirred
bioreactor (Kurazumi et al., 2011).
A further limit to RBC production in vitro is the red cell
yield per starting progenitor cell; the nature of the limit is
either availability or cost of the required starting cells.
The contribution of the starting cells to the cost of a final
RBC product depends on the proliferative capacity of the
cells during differentiation – every order of magnitude
in cell expansion (approximately 3.3 population dou-
blings) achieved between starting cells and final product
reduces the requirement for (and hence the impact of
the cost of) the starting cells by an order of magnitude
on a per product basis. Conversely, the impact on cost of
the final product for production of a given cell phenotype
becomes exponentially larger as the cells proliferate
towards terminal differentiation i.e. 2 × 1012 terminally
mature orthochromatic erythroblasts are required to
make each unit of enucleated blood, but only ~2 × 108
cells of the progenitor phenotype from ~14 PDs earlier
in the process. This is important as differentiating cells
have a changing profile of metabolism and other attri-
butes that impact manufacturing productivity cost; in
the case of red cells the potential to intensify would be
anticipated to increase as the cells mature. The different
approaches currently taken to overcome availability
limitation of primary cells such as UCB – pluripotent,
adult stem cell, engineered progenitor – will have differ-
ent production costs that will be a function of cost of input
cells and the subsequent proliferative capacity and
intensification profile during differentiation; very recent
progress to address both adult (vs. embryonic) matura-
tion (Fujita et al., 2016) and yield (Giani et al., 2016) from
renewable sources such as pluripotent cells has been
promising. Our work has focused on erythroblast intensi-
fication because it will be a key determinant of process
cost and practicality irrespective of the progenitor starting
cell population due to both the exceptionally high number
of these cells required in culture per unit of product and
their proliferative capacity (Mercier Ythier, 2015). The
data discussed here are therefore limiting and relevant
for any candidate red cell manufacture process.
We conclude that there are no conventional barriers
(shear stress sensitivity, O2 demand, or metabolic
demand) that would prevent established bioreactor
systems from producing blood at productivities under
100 l/unit, and possibly significantly higher. Further the
effect of combined control of pH, oxygen, and mechanical
agitation will greatly increase efficiency of final product
harvest; in particular mechanical agitation, by rapidly in-
creasing the proportion of enucleated cells, will enable
peak enucleation to be engineered closer to peak culture
system proliferation. This is absolutely key to reduce wast-
age of earlier enucleating cells, and to prevent challenging
downstream processing of low purity enucleated product.
However, the sensitivity of the cells to the bioprocess con-
ditions adds risk and complexity as well as opportunity;
mechanical stress may simultaneously increase
enucleation whilst reducing total proliferative capacity,
conventional biologics production strategies such as the
addition of cell membrane protective agents appear to im-
prove proliferation but reduce enucleation (presumably
because membrane mechanics are critical for enucle-
ation). To realize the potential efficiencies of production
at suitably low risk, process scaling and intensification
must be characterized for effects on all key elements of
cell quality, and effort must be focused on identifying
and mitigating the factor(s) that inhibit growth rate
(and hence media efficiency).
Key points
• Enucleated red cells can be produced to high purity in
industry standard stirred tank bioreactors at 500 l per
unit of cells
• Mass transfer and common metabolites are not primary
limitations indicating potential for substantially higher
efficiency
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